| CELLECTIS NOM. EO-,05 |
| Frankreich |
| Gesundheit |
| FR0010425595 / A0MKPR |
| ZVA (Frankfurt) |
| FRA:ZVA, ETR:ZVA, ZVA:GR |
| - |
| https://www.cellectis.com.. |
|
Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of next-generation immunotherapies for cancer. With over 25 years of innovation, Cellectis leverages its proprietary TALEN® gene-editing technology to engin..
>Volltext.. |
| 217.6 Mio. EUR |
| 142.06 Mio. EUR |
| 65.03 Mio. EUR |
| -18.96 Mio. EUR |
| -61.33 Mio. EUR |
| -0.61 EUR |
| 103.88 Mio. EUR |
| 55.08 Mio. EUR |
| -36.07 Mio. EUR |
| 1.43 |
| 66.75% |
| -78.8% |
| - |
| - |
| - |
| - |
| CELLECTIS |
| 04.04.26 |
|